Antenatal screening for cystic fibrosis: a trial of the couple model. 1994

J Livingstone, and R A Axton, and A Gilfillan, and M Mennie, and M Compton, and W A Liston, and A A Calder, and A J Gordon, and D J Brock
Human Genetics Unit, University of Edinburgh, Western General Hospital.

OBJECTIVE To assess the delivery and acceptability of antenatal couple screening for cystic fibrosis. Carrier status was notified only when both members of a partnership had cystic fibrosis alleles and therefore a one in four risk of having an affected child. METHODS Mouthwash samples were tested when both partners participated. Results were returned only to positive couples. METHODS Two large maternity hospitals in Edinburgh. METHODS Screening was offered to all couples who booked at one of the two hospitals. METHODS (a) The take up of screening, carriers and carrier couples identified, take up of prenatal diagnosis, and numbers of affected fetuses detected; (b) questionnaire measures of patient satisfaction and stress. RESULTS Screening was offered to 8536 couples. 714 (8.4%) were regarded as ineligible, usually because of late booking or absence of a partner. 1900 (24.3%) of the remainder declined screening. Among the 5922 screened couples, four tested positive--that is, both partners were cystic fibrosis heterozygotes. All four elected to have prenatal diagnosis. There were three terminations of pregnancy because of an affected fetus, one couple having two successive pregnancies with affected fetuses. The participation rate was 76% for eligible couples (5922/7822) and 69% for all couples (5922/8536). Only 89 screened couples (1.5%) requested information on individual carrier status. No anxiety was detected among a cohort of the screened population, and 99% of questioned participants expressed satisfaction with the concept of couple screening. CONCLUSIONS Antenatal couple screening is a satisfactory and acceptable way of screening for cystic fibrosis and has been adopted as routine in the two trial hospitals.

UI MeSH Term Description Entries
D008297 Male Males
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011296 Prenatal Diagnosis Determination of the nature of a pathological condition or disease in the postimplantation EMBRYO; FETUS; or pregnant female before birth. Diagnosis, Prenatal,Fetal Diagnosis,Fetal Imaging,Fetal Screening,Intrauterine Diagnosis,Antenatal Diagnosis,Antenatal Screening,Diagnosis, Antenatal,Diagnosis, Intrauterine,Prenatal Screening,Antenatal Diagnoses,Antenatal Screenings,Diagnosis, Fetal,Fetal Diagnoses,Fetal Imagings,Fetal Screenings,Imaging, Fetal,Intrauterine Diagnoses,Prenatal Diagnoses,Prenatal Screenings,Screening, Antenatal,Screening, Fetal,Screening, Prenatal
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D005260 Female Females
D005315 Fetal Diseases Pathophysiological conditions of the FETUS in the UTERUS. Some fetal diseases may be treated with FETAL THERAPIES. Embryopathies,Disease, Fetal,Diseases, Fetal,Embryopathy,Fetal Disease
D005817 Genetic Counseling An educational process that provides information and advice to individuals or families about a genetic condition that may affect them. The purpose is to help individuals make informed decisions about marriage, reproduction, and other health management issues based on information about the genetic disease, the available diagnostic tests, and management programs. Psychosocial support is usually offered. Counseling, Genetic,Genetic Counseling, Prenatal,Prenatal Genetic Counseling
D005820 Genetic Testing Detection of a MUTATION; GENOTYPE; KARYOTYPE; or specific ALLELES associated with genetic traits, heritable diseases, or predisposition to a disease, or that may lead to the disease in descendants. It includes prenatal genetic testing. Genetic Predisposition Testing,Genetic Screening,Predictive Genetic Testing,Predictive Testing, Genetic,Testing, Genetic Predisposition,Genetic Predictive Testing,Genetic Screenings,Genetic Testing, Predictive,Predisposition Testing, Genetic,Screening, Genetic,Screenings, Genetic,Testing, Genetic,Testing, Genetic Predictive,Testing, Predictive Genetic
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes
D006580 Genetic Carrier Screening Identification of individuals who are heterozygous at a GENETIC LOCUS for a recessive PHENOTYPE. Carriers, Genetic, Detection,Genetic Carriers, Detection,Heterozygote Detection,Carrier Detection, Genetic,Detection, Genetic Carrier,Genetic Carrier Detection,Heterozygote Screening,Carrier Screening, Genetic,Detection, Heterozygote,Screening, Genetic Carrier,Screening, Heterozygote,Screenings, Genetic Carrier

Related Publications

J Livingstone, and R A Axton, and A Gilfillan, and M Mennie, and M Compton, and W A Liston, and A A Calder, and A J Gordon, and D J Brock
February 1995, BMJ (Clinical research ed.),
J Livingstone, and R A Axton, and A Gilfillan, and M Mennie, and M Compton, and W A Liston, and A A Calder, and A J Gordon, and D J Brock
November 1993, Lancet (London, England),
J Livingstone, and R A Axton, and A Gilfillan, and M Mennie, and M Compton, and W A Liston, and A A Calder, and A J Gordon, and D J Brock
November 1991, Lancet (London, England),
J Livingstone, and R A Axton, and A Gilfillan, and M Mennie, and M Compton, and W A Liston, and A A Calder, and A J Gordon, and D J Brock
August 1996, British journal of obstetrics and gynaecology,
J Livingstone, and R A Axton, and A Gilfillan, and M Mennie, and M Compton, and W A Liston, and A A Calder, and A J Gordon, and D J Brock
May 1995, BMJ (Clinical research ed.),
J Livingstone, and R A Axton, and A Gilfillan, and M Mennie, and M Compton, and W A Liston, and A A Calder, and A J Gordon, and D J Brock
April 1996, BMJ (Clinical research ed.),
J Livingstone, and R A Axton, and A Gilfillan, and M Mennie, and M Compton, and W A Liston, and A A Calder, and A J Gordon, and D J Brock
April 1996, BMJ (Clinical research ed.),
J Livingstone, and R A Axton, and A Gilfillan, and M Mennie, and M Compton, and W A Liston, and A A Calder, and A J Gordon, and D J Brock
April 1995, Journal of medical genetics,
J Livingstone, and R A Axton, and A Gilfillan, and M Mennie, and M Compton, and W A Liston, and A A Calder, and A J Gordon, and D J Brock
December 1995, BMJ (Clinical research ed.),
J Livingstone, and R A Axton, and A Gilfillan, and M Mennie, and M Compton, and W A Liston, and A A Calder, and A J Gordon, and D J Brock
April 2003, Revue d'epidemiologie et de sante publique,
Copied contents to your clipboard!